Introduction:
Leading Pharma company has approved the merger of its promoter group firm to enhance market presence and operational efficiency. This strategic move aims to capitalize on growth opportunities in the healthcare and diagnostic sector, driving long-term value for shareholders.
Share price movement of Kopran:
On March 21, 2025, Kopran Ltd opened at ₹185.90, up 3.37% from its previous close of ₹179.85. The stock reached a high of ₹192.05 (7.26%) and a low of ₹181.60. By 12:58 PM, it traded at ₹187.65, a 4.34% increase, with a market cap of ₹889.66 crore.
Kopran Announces Merger for Expansion:
Kopran Ltd has announced the merger of its promoter group company, Kopran Laboratories Ltd, following board approval on March 20, 2025. The merger, subject to regulatory and shareholder approvals, aims to create synergies in the healthcare and diagnostic markets.
The merger will grant Kopran access to India’s fast-growing $14 billion diagnostic industry, projected to nearly triple by 2034. Kopran will leverage Kopran Laboratories’ network to market its products in hospitals and government institutions while repackaging and manufacturing diagnostic kits to enhance profitability.
This strategic move positions Kopran as an integrated healthcare and pharma company, boosting earnings per share (EPS) and shareholder value. The share exchange ratio has been set at 100 shares of Kopran Ltd for every 45 shares of Kopran Laboratories Ltd, aligning stakeholders’ interests in the growth strategy.
Recent news on Kopran:
As of February 17, 2025, Kopran Ltd reported a 12.63% decline in net sales to ₹71.94 crore for Q3 FY24. Net profit fell 12.97% to ₹7.41 crore, while EBITDA dropped 9.06% to ₹12.14 crore, reflecting financial pressures.
Ace investor holding in Kopran:
Madhuri Madhusudan Kela
Madhuri Madhusudan Kela holds 500,000 shares, representing a 1.04% stake in Kopran Ltd, with a total worth of ₹9.2 crore. This investment underscores confidence in the company’s growth potential within the pharmaceutical and healthcare sectors.
Stock performance of Kopran for Period of 1 week, 6 months, and 1 year:
Kopran Ltd reported a 12.1% gain over the past week, despite a 44.3% decline in the last six months and a 30.1% drop over the past year, reflecting ongoing volatility in its stock performance.
Also Read: NBFC stock jumps 5% after Bain Capital to acquire 26% stake in the company for ₹4,385 Cr
Shareholding pattern of Kopran:
| Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
| Promoter | 44.50% | 44.50% | 44.50% |
| FII | 0.90% | 1.30% | 0.70% |
| DII | 0% | 0.20% | 0.10% |
| Public | 54.70% | 54.00% | 54.70% |
About Kopran:
Kopran Ltd (NSE: KOPRAN) is a fully integrated pharmaceutical company engaged in manufacturing and supplying high-quality formulations and active pharmaceutical ingredients worldwide. With a strong global presence, it focuses on innovation and excellence in the pharmaceutical sector.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
